Washington University/Siteman Cancer Center Lead Academic Site

项目摘要 拟议中的华盛顿大学/西特曼癌症中心的根本目标 (WU/SCC)NCTN领先学术参与网站UG1将1)培养科学领导力和 在NCTN中的指导，2)参与NCTN治疗、相关、 和癌症控制试验，以及3)保持对多种疾病的临床试验的强劲收益 包括那些分子驱动的和那些罕见的癌症的。WU/SCC 调查人员在以前的合作小组中热情参与的历史由来已久 计划并继续在当前的NCTN计划中发挥关键作用，特别是联盟 肿瘤学临床试验、ECOG-ACRIN癌症研究小组和NRG肿瘤学。 WU/SCC将有5名UG1联合首席调查员组成高级领导团队 包括Nancy L.Bartlett医学博士(医学肿瘤学教授)、Benjamin Kozower医学博士、公共卫生硕士 (胸科肿瘤学教授)，David G.Mutch医学博士(妇科肿瘤学教授)， Clifford Robinson医学博士(放射肿瘤学副教授)和Barry A.Siegel医学博士 (放射学教授)吴/SCC高级领导团队由三个遗产组成 具有广泛合作小组和NCTN经验的成员(Bartlett、Mutch和Siegel) 以及两名具有NCTN试验开发经验的新成员(罗宾逊和科佐尔)。 整个领导团队致力于为机构范围的NCTN提供指导 UG1。WU/SCC一直表现出对NCTN试验的强劲收益，累计848 2014年3月至2017年8月期间的患者。在同一时间间隔内，患者有 收集的生物标本和58名患者被累积到高级成像研究。这个 WU/SCC基因组学、蛋白质组学和分子成像程序在 与大型机构生物库的结合使我们能够使意义重大和新颖 对NCTN科学任务的贡献。WU/SCC调查人员保持高度重视 投资于NCTN在急性髓细胞白血病、淋巴瘤、肺癌、乳腺癌方面的翻译和临床研究 癌症、肉瘤、子宫癌、分子成像和放射肿瘤学。此外，我们的 我们中心的转诊基数很大，新发癌症病例大幅增加 在过去的5年里，我们将增强我们让患者遵守几乎所有疾病现场协议的能力， 包括罕见的肿瘤。这一机构范围的UG1将促进加强沟通和 疾病现场、翻译和医疗保健专家之间的协作，并改善我们的 对NCTN业务做出贡献的潜力。

Project Summary The fundamental goal of the proposed Washington University/Siteman Cancer Center (WU/SCC) NCTN Lead Academic Participating Site UG1 is to 1) foster scientific leadership and mentorship in the NCTN, 2) participate in the development of NCTN therapeutic, correlative, and cancer control trials, and 3) maintain strong accrual to clinical trials across multiple disease sites, including those that are molecularly driven and those for rare cancers. WU/SCC investigators have a long history of enthusiastic participation in the former cooperative group program and continue to play key roles in the current NCTN program, specifically the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology. WU/SCC will have 5 UG1 co-Principal Investigators comprising the senior leadership team including Nancy L. Bartlett, MD (Professor, Medical Oncology), Benjamin Kozower, MD, MPH (Professor, Thoracic Oncology), David G. Mutch, MD (Professor, Gynecologic Oncology), Clifford Robinson, MD (Associate Professor, Radiation Oncology) and Barry A. Siegel, MD (Professor, Radiology). The WU/SCC senior leadership team is composed of three legacy members with extensive cooperative group and NCTN experience (Bartlett, Mutch and Siegel) and two new members (Robinson and Kozower) with experience in NCTN trial development. The entire leadership team is committed to providing guidance for an institution-wide NCTN UG1. WU/SCC has consistently demonstrated robust accrual to NCTN trials, accruing 848 patients between March 2014 and August 2017. During this same interval, 535 patients had biospecimens collected and 58 patients were accrued to advanced imaging studies. The strength of the WU/SCC genomics, proteogenomics, and molecular imaging programs in combination with the large institutional biorepositories position us to make significant and novel contributions to the scientific mission of the NCTN. WU/SCC investigators remain highly invested in NCTN translational and clinical research in AML, lymphoma, lung cancer, breast cancer, sarcoma, uterine cancer, molecular imaging, and radiation oncology. In addition, our large referral base and the substantial increase in new cancer cases seen at our center in the last 5 years will enhance our ability to accrue patients to nearly all disease site protocols, including rare tumors. This institution-wide UG1 will facilitate enhanced communication and collaboration among disease-site, translational, and modality specialists and improve our potential for contributions to the NCTN operation.